Background : Peptic ulcer patients need to be treated with antimicrobials to cure Helicobacter pylori infection. Seven-day quadruple therapy is the regimen with the highest cure rates. An ultra-short quadruple therapy was evaluated prospectively. Methods : Forty-six consecutive H. pylori positive patients (33 had proven ulcer disease) were prescribed lansoprazole 30 mg b.d. on days 1-4, and on day 4 they received in addition tripotassium dicitrato bismuthate 120 mg, tetracycline 250 mg and metronidazole 250 mg at 09
INTRODUCTION
Eradication of Helicobacter pylori from the stomach cures peptic ulcer disease. Therefore all ulcer patients infected with this organism should receive antimicrobial therapy"
-' and cure of the infection has become the goal of treatment. Most anti-Helicobacter therapies need to be given for 7-14 days$ ,% and therefore are usually prescribed to out-patients. Ulcer healing is more rapid and more complete when H. pylori is eradicated( -"! and in theory early eradication may improve prognosis. Patients
Results : Follow-up was complete. Overall cure rate (all three biopsy-based tests negative) was 26\46 (57 % ; 95 % CI : 41-71 %). Antibiotic sensitivity was available in 42. Thirty-nine carried a metronidazole sensitive strain and 23\39 (59 %) were cured, three carried a resistant strain and therapy failed in all. Three out of four in whom susceptibility was unknown were cured. Metronidazole resistance was induced in 8 out of 16 with a sensitive strain. Only one patient (3 %) reported severe side effects. Conclusions : This convenient quadruple regimen showed that a short contact time is sufficient to kill H. pylori in vivo. Since 57 % of patients are cured with a 14-h treatment, a slightly longer treatment duration may increase the cure rate to above 90 %.
admitted with a gastrointestinal bleed and an active ulcer usually are admitted for less than 1 week."" ,"# For these patients, very short but highly effective therapies that can be finished during the hospital stay may be useful.
Quadruple therapy consisting of a proton pump inhibitor, a bismuth salt, tetracycline and metronidazole is presently the therapy with the highest cure rates.$ ,%,"$ Its optimal treatment duration is 7 days ; it has a near 100 % cure rate and can overcome pre-treatment metronidazole resistance.* ,"% -"* It is the only regimen that has achieved 90 % cure in treatments less than 7 days.#! Four day therapy has a 95 % cure rate in metronidazole sensitive strains, but at present there are insufficient data to judge its efficacy in resistant strains.#! ,#" Tucci et al. showed 90 % cure rates in sensitive strains with 2 days of quadruple therapy, with amoxicillin instead of tetracycline.## A Japanese group cured 96 % of patients when giving quadruple therapy topically, after rinsing the stomach with the antibiotic cocktail for 1 h while obstructing the pylorus with a balloon catheter.#$ These data show that a short contact time is sufficient to kill H. pylori in vivo.
In the present study we have tried to reproduce the good results of the 1-h topical therapy by dosing the quadruple therapy components eight times a day with 2-h intervals. The efficacy and tolerability of this ultra-short intensified convenient quadruple therapy was evaluated prospectively in an open study.
MATERIALS AND METHODS
All our patients who were thought to be candidates for anti-Helicobacter treatment between July 1995 and February 1996 received ultra-short quadruple therapy. These consecutive patients were all H. pylori positive in endoscopic biopsies. No other anti-Helicobacter regimens were used in the same period. Patients were pre-treated with lansoprazole 30 mg b.d. on days 1-4 and on day 4 they received in addition tripotassium dicitrato bismuthate 120 mg, tetracycline hydrochloride 250 mg and metronidazole 250 mg at 09.00, 11.00, 13.00, 15.00, 17.00, 19.00, 21.00 and at 23.00 hours.
Endoscopy
All patients were investigated by endoscopy, both before and 6 weeks after treatment. During both endoscopies, H. pylori status was determined by a standard set of seven biopsies. Two biopsies (one from the antrum and one from the corpus) were investigated in a CLOtest duo (Delta-West, Australia) which contains two agar cups and permits the separate detection of urease activity in antral and corpus biopsies. Four biopsies (two from the antrum and two from the corpus) were collected for histology and investigated with a modified Giemsa stain. One biopsy from the antrum was collected for bacterial culture and antimicrobial susceptibility testing. A patient was considered to be cured if all three tests were negative at the follow-up endoscopy.
RESULTS
Forty-six patients entered the study. There were 30 male and 16 female patients. Mean age 54n8 years (range 24-86 years). There were 22 smokers (48 %). Indications for treatment were proven duodenal ulcer disease (n l 25), proven gastric ulcer disease (n l 7) or functional dyspepsia (n l 13). One patient presented with a duodenal ulcer but later turned out to have a pancreatic cancer infiltrating the duodenal bulb. The functional dyspepsia group includes patients without documented evidence of ulceration.
Follow-up data were available for all patients. The results of both endoscopies are shown in Tables 1 and 2 . Overall cure rate was 26 out of 46 patients (57 %) (95 % CI : 41-71 %). Eighteen of 20 patients had at least three positive tests and must be considered true treatment failures. However, two patients only had one positive CLOtest and all other tests negative. Although these two were counted as treatment failures they could have had a false-positive CLOtest and therefore the actual cure-rate could have been slightly higher.
Forty-three patients (94 %) had a positive culture pretreatment. An antibiogram was obtained in 42. All were clarithromycin sensitive. Thirty-nine (93 %) were metronidazole sensitive and three (7 %) metronidazole resistant. Twenty-three out of 39 patients (59 %) carrying a sensitive strain were cured vs. none of the three carrying a resistant strain. Three of the four patients in 
whom an antibiogram was unavailable were cured. Of the 16 patients with metronidazole sensitive strains who were not cured, two had a negative culture posttreatment and in one, obtaining an antibiogram failed. Five failures had remained metronidazole sensitive, but eight had become metronidazole resistant. Of the three patients with metronidazole resistant strains who were not cured obtaining an antibiogram failed in one, the second had remained resistant but the third had become metronidazole sensitive post-treatment.
Side effects and compliance
Collection of side effect data was by use of a standard questionnaire#% which was filled out by 39\46 (85 %) of the patients. Anorexia was reported by five (13 %), nausea by 10 (26 %), vomiting by one (3 %), taste disturbance by 13 (33 %), dizziness by 13 (33 %), belly pain by 6 (15 %), diarrhoea during treatment by 6 (15 %), diarrhoea after treatment by 13 (33 %) and headache by 16 (41 %). Symptoms were almost always mild, which is reflected in the overall judgement on the tolerability on a five-point scale.#% Ten (26 %) reported no side effects, 26 (67 %) mild side effects not interfering with daily activities, two (5 %) reported moderate side effects interfering with daily activities and one (3 %) reported severe side effects. No patient selected the fifth option : premature treatment cessation due to severe side effects. Compliance (determined by pill count) was 100 % in all patients.
DISCUSSION
When compared to other regimens, quadruple therapy provides the most consistent and highest cure rates.$ ,% In randomized studies it was superior to omeprazole monotherapy,* dual therapy,"% bismuth based triple therapy"& ,"',#& and bismuth based triple therapy plus an histamine H # receptor antagonist.#' Due to its better intrinsic anti-Helicobacter activity in vitro#( -#* and its superior acid inhibition the first few days of therapy$! ,$" it is attractive to use lansoprazole in quadruple regimens. We consider 7 days of quadruple therapy as the new ' gold standard ' therapy to which newer regimens should be compared."$ ,## Although its high efficacy is not disputed, some investigators have argued that quadruple regimens are too complex and that they may induce too many side effects.$$ ,$% The 4-day quadruple therapy, due to its shortness and good tolerability, can overcome some of these worries. However, its efficacy might be a problem in areas with a high prevalence of metronidazole resistance.#! ,#"
In this study we tried to overcome the limitations of quadruple therapy by investigating a convenient 1-day anti-Helicobacter regimen. This regimen, with a cure rate of 57 % had a much lower cure rate than the 96 % achieved with a 1-h topical therapy#$ and its moderate efficacy rules out its use in clinical care. The present study did however demonstrate the high efficacy of the quadruple therapy components. In some patients, 1-day treatment apparently is sufficient for cure. The occurrence of metronidazole resistance in at least 8 of the 16 patients who had a metronidazole sensitive strain pretreatment may explain some of the failures. It is unclear whether this is due to the selection of existing metronidazole resistant substrains or true transformation from a metronidazole sensitive into a resistant strain. In others, who had remained metronidazole sensitive, host factors related to acid secretion, motility, thickness of the mucous layer, shape of the stomach etc. may all have contributed to inadequate distribution and inadequate concentration of the drugs through all parts of the stomach, and thus may account for the failure to eradicate H. pylori. Interestingly, one patient with a metronidazole resistant isolate pre-treatment had a sensitive isolate post-treatment. Metronidazole resistance can be unstable and therefore temporary,$& which may explain this observation. Alternatively some patients may be infected with multiple strains$' and we might have isolated a different strain on both occasions.
Further studies must explore slightly longer treatment duration or a different dosing schedule of quadruple therapy. Since around 57 % of patients are cured on day 1, a slightly longer treatment or a higher dose of metronidazole might be sufficient to increase the cure rate to above 90 %. These results suggest that premature treatment discontinuation is not a serious threat for the overall efficacy of the standard 7-day quadruple therapy.
